JP2004513093A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004513093A5 JP2004513093A5 JP2002535640A JP2002535640A JP2004513093A5 JP 2004513093 A5 JP2004513093 A5 JP 2004513093A5 JP 2002535640 A JP2002535640 A JP 2002535640A JP 2002535640 A JP2002535640 A JP 2002535640A JP 2004513093 A5 JP2004513093 A5 JP 2004513093A5
- Authority
- JP
- Japan
- Prior art keywords
- glass
- component
- subject
- delivering
- bioactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011521 glass Substances 0.000 claims 5
- 230000000975 bioactive effect Effects 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000005365 phosphate glass Substances 0.000 claims 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims 2
- 239000012867 bioactive agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Claims (1)
上記の第一の成分が、上記の生物活性剤を含有した、糖ガラス、金属カルボキシレートガラスまたはホスフェートガラスの微粒子からなり、上記の糖ガラス、金属カルボキシレートガラスまたはホスフェートガラスが場合によりガラス形成促進剤化合物を含有し、
上記の第二の成分が、上記の第一の成分が不溶性でかつ分散される少くとも１種の生物適合性液体ペルフルオロカーボンからなり、その液体ペルフルオロカーボンが場合により界面活性剤を含有している、上記組成物を、ヒトである対象者へ投与するステップからなる、上記対象者へ生物活性物質をデリバリーするための方法。A composition for delivering a stable bioactive compound to a subject comprising a first component and a second component comprising:
The first component is composed of fine particles of sugar glass, metal carboxylate glass or phosphate glass containing the bioactive agent described above, and the sugar glass, metal carboxylate glass or phosphate glass may optionally promote glass formation. Containing an agent compound,
The second component comprises at least one biocompatible liquid perfluorocarbon in which the first component is insoluble and dispersed, the liquid perfluorocarbon optionally containing a surfactant. A method for delivering a bioactive substance to a subject comprising administering the composition to a subject who is a human.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/028244 WO2002032402A1 (en) | 2000-10-13 | 2000-10-13 | Composition and method for stable injectable liquids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003383800A Division JP4027881B2 (en) | 2003-11-13 | 2003-11-13 | Compositions and methods for stable injections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004513093A JP2004513093A (en) | 2004-04-30 |
| JP2004513093A5 true JP2004513093A5 (en) | 2005-08-04 |
Family
ID=21741883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002535640A Withdrawn JP2004513093A (en) | 2000-10-13 | 2000-10-13 | Compositions and methods for stable injections |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1328255A1 (en) |
| JP (1) | JP2004513093A (en) |
| KR (1) | KR20030096224A (en) |
| CN (1) | CN100339066C (en) |
| AU (2) | AU1198601A (en) |
| CA (2) | CA2689856C (en) |
| ES (1) | ES2337252T3 (en) |
| MX (1) | MXPA03003236A (en) |
| NO (1) | NO20031706L (en) |
| PL (1) | PL360052A1 (en) |
| PT (1) | PT1452171E (en) |
| WO (1) | WO2002032402A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004037293A1 (en) * | 2002-10-22 | 2006-02-23 | 大日本住友製薬株式会社 | Stabilizing composition |
| JP2007001865A (en) * | 2003-09-16 | 2007-01-11 | Ltt Bio-Pharma Co Ltd | Fine particle enclosing fat-soluble medicine, method for producing the same and preparation containing the same |
| JP2007532619A (en) | 2004-04-13 | 2007-11-15 | ケンブリッジ バイオスタビリティ リミテッド | Liquid containing suspended glass particles |
| GB0408199D0 (en) * | 2004-04-13 | 2004-05-19 | Cambridge Biostability Ltd | Liquids containing suspended sugar glass particles |
| GB2430880A (en) * | 2005-10-04 | 2007-04-11 | Cambridge Biostability Ltd | Pharmaceutical compositions stabilized in glassy particles |
| GB0523638D0 (en) * | 2005-11-21 | 2005-12-28 | Cambridge Biostability Ltd | Pharmaceutical device for the administration of substances to patients |
| US8946200B2 (en) | 2006-11-02 | 2015-02-03 | Southwest Research Institute | Pharmaceutically active nanosuspensions |
| CN101932317B (en) * | 2008-01-18 | 2013-03-27 | 旭化成制药株式会社 | Stable pharmaceutical composition |
| US8404850B2 (en) | 2008-03-13 | 2013-03-26 | Southwest Research Institute | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors |
| US8722706B2 (en) | 2008-08-15 | 2014-05-13 | Southwest Research Institute | Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts |
| US8309134B2 (en) | 2008-10-03 | 2012-11-13 | Southwest Research Institute | Modified calcium phosphate nanoparticle formation |
| WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
| WO2011007327A2 (en) | 2009-07-16 | 2011-01-20 | Koninklijke Philips Electronics N.V. | Suspension for therapeutic use and device for delivering said suspension |
| ES2362525B8 (en) | 2009-10-08 | 2013-01-03 | Azurebio, S.L. | Medication formulation in the form of penetrating percutaneous needles. |
| US9028873B2 (en) | 2010-02-08 | 2015-05-12 | Southwest Research Institute | Nanoparticles for drug delivery to the central nervous system |
| CN109094212B (en) | 2014-03-24 | 2021-03-19 | 精工爱普生株式会社 | Tape printing apparatus |
| WO2015145353A1 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR78151B (en) * | 1982-04-05 | 1984-09-26 | Alcon Lab Inc | |
| US5518731A (en) * | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
| WO1993018748A1 (en) * | 1992-03-19 | 1993-09-30 | Allergan, Inc. | Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid |
| GB9705588D0 (en) * | 1997-03-18 | 1997-05-07 | Anglia Research Foundation | Stable particle in liquid formulations |
| US6190701B1 (en) * | 1999-03-17 | 2001-02-20 | Peter M. Ronai | Composition and method for stable injectable liquids |
-
2000
- 2000-10-13 AU AU1198601A patent/AU1198601A/en active Pending
- 2000-10-13 EP EP00973483A patent/EP1328255A1/en not_active Withdrawn
- 2000-10-13 PT PT04013422T patent/PT1452171E/en unknown
- 2000-10-13 PL PL00360052A patent/PL360052A1/en unknown
- 2000-10-13 CA CA2689856A patent/CA2689856C/en not_active Expired - Lifetime
- 2000-10-13 CN CNB008199655A patent/CN100339066C/en not_active Expired - Fee Related
- 2000-10-13 CA CA2424656A patent/CA2424656C/en not_active Expired - Lifetime
- 2000-10-13 WO PCT/US2000/028244 patent/WO2002032402A1/en active IP Right Grant
- 2000-10-13 ES ES04013422T patent/ES2337252T3/en not_active Expired - Lifetime
- 2000-10-13 MX MXPA03003236A patent/MXPA03003236A/en active IP Right Grant
- 2000-10-13 JP JP2002535640A patent/JP2004513093A/en not_active Withdrawn
- 2000-10-13 AU AU2001211986A patent/AU2001211986B2/en not_active Ceased
- 2000-10-13 KR KR10-2003-7004941A patent/KR20030096224A/en active Search and Examination
-
2003
- 2003-04-11 NO NO20031706A patent/NO20031706L/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004513093A5 (en) | ||
| ES2569949T3 (en) | Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine | |
| WO1999059544A3 (en) | Orally disintegrable tablets | |
| CA2281473A1 (en) | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same | |
| WO2002045684A3 (en) | Rapidly dispersing pharmaceutical composition comprising effervescent agents | |
| AU2003304237A1 (en) | Gel-stabilized nanoparticulate active agent compositions | |
| ATE232382T1 (en) | PHARMACEUTICAL COMPOSITIONS WITH RAPID RELEASE OF ACTIVE INGREDIENTS | |
| DK1429731T3 (en) | Nanoparticle formulations containing insulin | |
| IT1246350B (en) | METHOD FOR OBTAINING A RAPID SUSPENSION OF INSOLUBLE DRUGS IN WATER | |
| WO2002049676A3 (en) | Compositions containing inclusion complexes | |
| BG102228A (en) | Medicamentous form with controlled release of slightly soluble medicamentous substances | |
| EP2298279A3 (en) | Pharmaceutical compositions for inhalation | |
| WO2004017907A3 (en) | Blood clot-targeted nanoparticles | |
| ATE521343T1 (en) | COMPOSITIONS OF RASAGILIN THAT DISSOLVE IN THE MOUTH | |
| HK1076379A1 (en) | Use of a composition comprising anti-vla-1 antibody for the preparation of a pharmaceutical composition for the treatment of pulmonary fibrosis | |
| TNSN99173A1 (en) | DELIVERY OF ACTIVE AGENT IN THE FORM OF DRY POWDER | |
| CA2340898A1 (en) | Compositions and methods for treating intracellular infections | |
| SI1561460T1 (en) | Nanoparticles for the administration of active ingredients, method of producing said particles and composition containing same | |
| HUP0300221A3 (en) | Use of oltipraz as an antifibrotic and anticirrhotic agent in the liver for producing pharmaceutical compositions and pharmaceutical compositions containing oltipraz and process for producing them | |
| HUP9802897A3 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient | |
| WO2003026574A3 (en) | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy | |
| EP0787498A3 (en) | Therapeutic human albumin having a low aluminium binding capacity | |
| CA2305764A1 (en) | Bile acid salts of metals with physiological action and the use thereof in therapy | |
| BR0202759A (en) | Modified release pharmaceutical composition containing bupropion as active substance | |
| JPH04149132A (en) | Aqueous solution of danazol |